Glycemic Index of Table Grape Varietals

Investigation of the Glycemic Index of Table Grape Varietals

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03248609

Enrollment

Registered

2017-08-14

Start date

2017-07-31

Completion date

2018-06-04

Last updated

2019-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Investigate the postprandial glycemic responses of healthy individuals when consuming commercially available table grape varietals or grape juice, compared to a standard amount of glucose.

Detailed description

The study aims to investigate the postprandial glycemic responses of healthy individuals when consuming commercially available table grape varietals, compared to a standard amount of glucose. The study also aims to evaluate a new grape varietal, compared to other common table grapes, with regard to glycemic index and metabolic response related to inflammation.

Interventions

OTHERMilano grapes

Milano grapes to test post-prandial glycemic response

OTHERTable grapes

Table grapes to test post-prandial glycemic response

OTHERGrape juice

Grape juice to test post-prandial glycemic response

OTHERGlucose beverage

Standardized glucose beverage to test post-prandial glycemic response

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

21 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy men and women * 21-75 years of age * BMI range 20-35

Exclusion criteria

* adults unable to consent, individuals who are not yet adults (children), pregnant women, and prisoners. * BMI of \>35 or morbid obesity. * Diagnosed type 1 or 2 diabetes, fasting blood glucose of \>125 mg/dl, or reported use of medications or supplements known to affect glucose metabolism (insulin, sulfonylureas, metformin, glucosidase inhibitors, thiazolidinedione, insulin sensitizers, GLP-1 mimetics). * Medications known to affect gastrointestinal motility (prokinetic agents such as reglan). * Renal, liver, pancreatic or cardiovascular disease, uncontrolled hypertension of \> 160/90, inflammatory bowel disease, disorders of esophageal and gastrointestinal motility, previous gastric resection or restriction procedures, autoimmune or immunologic disorders, anemia, breastfeeding women * Food allergy to grapes, or inability to tolerate gluten (celiac disease). * Poor venous access. * Smoking, illicit drug use, consuming \>7 alcoholic drinks per week. * Weight gain or loss of \> 5 kg within the prior 6 months. * Unwillingness to adhere to study protocol.

Design outcomes

Primary

Measure	Time frame	Description
Glycemic Index	3 hours	The post-prandial glucose and insulin responses in healthy individuals to glucose containing foods or beverages.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026